Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 13Completed 8Unknown 5Terminated 3Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Other hematologic neoplasm 5Genitourinary 4Breast 4Thoracic 3Lymphoid 3Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other 1Myeloid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Blood Specimen Collection × Sarcoma × Clear all
NCT05854966 2024-09-19

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Wake Forest University Health Sciences

Phase 2 Withdrawn
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡